<DOC>
	<DOCNO>NCT02140996</DOCNO>
	<brief_summary>In epithelial cancer , MUC-1 ( mucin-1 ) overexpression think disrupt E-cadherin function , lead anchorage-independent tumor cell growth metastasis . Elevated level MUC-1 expression find patient epithelial cancer breast , ovarian , colon lung . Furthermore , overexpression MUC-1 independently correlate adverse clinical phenotype , metastasis resistance chemotherapy . In animal model , suppress expression MUC-1 reduce rate growth metastasis increase sensitivity cancer chemotherapy-induced cell death . In study , adenoviral Ad-sig-hMUC-1/ecdCD40L vector encode fusion protein hMUC-1 epithelial antigen attach CD40L ( CD40 ligand ) . The preclinical result also show two subcutaneous Ad-sig-hMUC-1/ecdCD40L vector injection induce immunity activation dendritic cell promotion antigen specific B cell antigen specific CD8 effector T cell suppress growth hMUC-1 tumor cell 100 % vaccinated mouse without Interleukin ( IL ) 2 stimulation require , suggest Ad-sig-hMUC-1/ecdCD40L vector prime-hMUC-1/ecdCD40L protein boost potential effective vaccine epithelial tumor . Therefore , safety tolerability Ad-sig-hMUC-1/ecdCD40L vector vaccine test phase I non-randomized open label dose escalation trial men woman metastatic recurrent epithelial cancer lung , breast , ovary , prostate colon .</brief_summary>
	<brief_title>Safety Study Human MUC-1 ( Mucin-1 ) Adenoviral Vector Vaccine Immunotherapy Epithelial Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Men woman age 21 yr old biopsyproven recurrent metastatic , measurable nonmeasurable adenocarcinoma breast , ovary , lung , colon prostate . 2 . Elevated serum MUC1 level [ measure Carcinoma Antigen ( CA ) 153 CA27.29 ] time since diagnosis cancer ( level need elevate time trial entry ) . 3 . Received least one line palliative chemotherapy . 4 . No chemotherapy and/or radiation therapy least 28 day consent . 5 . An echocardiogram show leave ventricular ejection fraction great equal low limit normal . 6 . Electrocardiogram ( ECG ) evidence ischemia infarction . 7 . Ability understand study 's risk , benefit , procedure provide write informed consent . 8 . Performance status &lt; 2 Eastern Cooperative Oncology Group ( ECOG ) performance scale life expectancy great 12 month . 9 . Acceptable pulmonary function . ( If questionable pulmonary function test perform . ) 10 . Negative serology hepatitis B [ hepatitis B surface antigen ( HBsAg ) negative ] , hepatitis C human immunodeficiency virus ( HIV ) . 11 . All following : white blood count &gt; 3500 , absolute neutrophil count &gt; /= 1,500 , hemoglobin &gt; 8 g/dL , platelet count &gt; 100,000/dL : Bilirubin &lt; 1.5 , AST ( aspartate aminotransferase ) , ALT ( alanine aminotransferase ) , LDH ( Lactate dehydrogenase ) &lt; 2 time upper limit normal , calculated creatinine clearance &gt; /= 50 mls/min . 12 . For woman childbearing potential : negative urinary pregnancy test screening within 7 day enrollment ; men woman : willingness use approve contraceptive method participate trial . Documentation type contraception patient use must include screen visit note investigator . 1 . History bronchospasm asthma require steroid treatment ( inhaled oral ) . 2 . Treatment steroid ( condition , except chemotherapy premedication emesis ) within 28 day trial registration . 3 . Current anticancer treatment doxorubicin ( Adriamycin ) , lapatinib , trastuzumab , bevacizumab monoclonal antibody therapy . Patients must therapies least 28 day . Patients may expose chemotherapy radiation therapy 4 week prior receive vaccination . 4 . Current anticancer treatment tamoxifen . Patients must tamoxifen least 28 day prior enrollment . ( Aromatase inhibitor raloxifene allow ) . 5 . History autoimmune disease lupus , rheumatoid arthritis psoriasis . 6 . Uncontrolled diabetes mellitus . 7 . Unable unwilling undergo repeat clinical evaluation diagnostic procedure unable sign inform consent . 8 . History malignancy except squamous basal cell carcinoma skin cervical carcinoma situ . 9 . History organ transplant allogeneic bone marrow transplant . 10 . Pregnant nursing female . 11 . Any acute chronic viral , bacterial , fungal infection require specific therapy . Acute therapy must complete within 14 day prior study treatment . 12 . Any underlying condition would contraindicate therapy study treatment ( allergies reagent use study treatment ) . 13 . Any history cardiac disease include arrhythmia ( require active treatment medication ) , heart failure , angina , infarction coronary artery disease . 14 . History hypercoagulable disorder include history prior pulmonary embolism , antiphospholipid antibody syndrome , deep venous thrombosis [ except indwell intravenous catheter associate DVT ( deep vein thrombosis ) , long patient complete anticoagulation therapy ] . 15 . Any brain leptomeningeal involvement cancer . 16 . Known Ornithine transcarbamylase deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MUC-1 vector vaccine ; epithelial cancer ; immunotherapy ; safety ; antigen specific vaccine , dendritic cell activation</keyword>
</DOC>